Pemziviptadil - PhaseBio Pharmaceuticals
Alternative Names: PB 1046; VasomeraLatest Information Update: 03 Mar 2022
At a glance
- Originator PhaseBio Pharmaceuticals
- Class Anti-inflammatories; Antifibrotics; Antihypertensives; Cardiovascular therapies; Heart failure therapies; Peptide hormones; Recombinant fusion proteins
- Mechanism of Action Vasoactive intestinal peptide type II receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Cardiomyopathies; Heart failure; Pulmonary arterial hypertension; SARS-CoV-2 acute respiratory disease
- No development reported Cystic fibrosis; Essential hypertension
Most Recent Events
- 04 Feb 2022 PhaseBio Pharmaceuticals terminates a phase II long-term extension trial for Pulmonary arterial hypertension in USA (NCT03795428)
- 21 Dec 2021 PhaseBio Pharmaceuticals suspends a phase II long-term extension trial for Pulmonary arterial hypertension in USA (NCT03795428)
- 21 Dec 2021 PhaseBio Pharmaceuticals terminates a phase II trial in Pulmonary arterial hypertension in USA, Spain, Hungary, Poland, Greece, Bulgaria and Austria (SC) due to COVID-19 impacts, associated drug supply and the rate of enrolment (NCT03556020)